Takeda reported that zasocitinib, the oral TYK2 inhibitor it acquired in a multibillion-dollar deal, met primary and key secondary endpoints in two Phase 3 plaque psoriasis studies. Company statements said more than half of treated patients achieved 'clear or almost clear' skin at four months, with a meaningful portion reaching completely clear outcomes. Takeda plans regulatory filings in 2026 and will present detailed data at an upcoming medical meeting. The results validate Takeda’s $4 billion acquisition strategy and position zasocitinib as a new oral competitor in an increasingly crowded immune‑modulatory market.